Wolverine Peptide Blend (BPC-157 + TB-500): Research Guide and Where to Buy
Wolverine Peptide Blend (BPC-157 + TB-500): Research Guide and Where to Buy
Published: 2026 · Updated: 2026
Research use only. Nothing here is medical advice, a dosing protocol, or a human-use recommendation. BPC-157 and TB-500 are not approved by the FDA for human use. The concentration math further down is standard laboratory reconstitution arithmetic for handling a research sample, not an instruction to administer anything to a person or animal.
The Wolverine peptide blend is a research-use-only combination of BPC-157 and TB-500 (a synthetic thymosin beta-4 peptide), co-lyophilized in one vial at a fixed 1:1 mass ratio, most often 10 mg + 10 mg for 20 mg total. It is a grey-market nickname for the pair, not an approved drug or a patented molecule.
Labs work with the two together because they map to complementary repair pathways in the preclinical literature: BPC-157 is studied mostly in localized connective-tissue models, TB-500 in systemic cell migration and angiogenesis. That is a rationale for pairing them in a study design, not evidence that one “boosts” the other in a living subject.
What the Wolverine blend actually is
The name is a fandom nickname, not a formulation standard. Across the grey market, “Wolverine” almost always means a single vial containing BPC-157 + TB-500 in a 1:1 mass ratio, most commonly 10 mg + 10 mg for 20 mg total peptide content. There is no branded or patented “Wolverine” compound; the label describes the pair, not a proprietary molecule.
Two facts matter more than the marketing:
- It is co-lyophilized. Both peptides are freeze-dried together in the same vial. Once reconstituted, every microliter drawn contains both peptides in the same fixed ratio. You cannot titrate one independently of the other out of a blended vial.
- The label is a claim; the COA is the measurement. A vial stamped “10mg/10mg” states a manufacturing target. The only number that reflects what is physically in the glass is a lot-matched Certificate of Analysis (COA) showing HPLC purity and mass-spec identity for that specific lot number.
The two components at a glance
| Property | BPC-157 | TB-500 (thymosin beta-4 peptide) |
|---|---|---|
| Class | Synthetic pentadecapeptide (15 aa), a partial sequence of a protein found in gastric juice | Synthetic form of thymosin beta-4; sold as the full 43-aa protein or a shorter actin-binding fragment (vendors vary) |
| Approx. molecular weight | ~1419 Da | Full thymosin beta-4 protein ~4963 Da; the core actin-binding motif is 7 residues (LKKTETQ) |
| Primary preclinical research focus | Localized tendon-, ligament-, and gut-tissue models; angiogenesis; fibroblast behavior | Actin sequestration; cell migration; angiogenesis; systemic wound and cardiac models |
| Proposed mechanism (research) | VEGFR2 / angiogenic signaling; growth-hormone-receptor upregulation in tendon fibroblasts | G-actin sequestration enabling cytoskeletal remodeling and cell migration |
| FDA human-use status | Not approved for human use; 503A compounding status under active FDA review in 2026 (see below) | Not approved for human use; also part of the 2026 FDA 503A compounding review |
| WADA status | Prohibited at all times (S0, non-approved substances; added 2022) | Prohibited at all times (S2, growth factors; thymosin beta-4 and its derivatives, e.g. TB-500) |
Both peptides sit on the WADA Prohibited List, so any research subject in tested sport is disqualified by their presence. That is a checkable fact worth stating plainly rather than burying.
On the regulatory side, neither peptide is approved by the FDA for human use, and BPC-157’s standing under the FDA’s Section 503A compounding framework is unsettled as of 2026. It appeared on the interim Category 2 list (bulk substances flagged as raising significant safety concerns), but the FDA has since moved it back into review and proposed not adding BPC-157 or TB-500 to the 503A Bulks List, with a Pharmacy Compounding Advisory Committee session scheduled for July 2026. Treat the specifics as a moving target and check the current FDA listing yourself before relying on any of it.
Why BPC-157 and TB-500 are studied together
The rationale in the literature is complementary pathways, not synergy demonstrated in people. No controlled human trial of the pair exists.
BPC-157 is the more locally-studied of the two. In transected rat Achilles tendon models it improved healing across biomechanical, functional, and histological measures and stimulated tendocyte growth in vitro (Staresinic et al., J Orthop Res, 2003). A separate rat model of Achilles detachment reported improved tendon-to-bone healing and blunting of corticosteroid-induced impairment (Krivic et al., J Orthop Res, 2006). Mechanistic work found BPC-157 promoted tendon fibroblast outgrowth, survival under oxidative stress, and migration (Chang et al., J Appl Physiol, 2011) and dose-dependently upregulated the growth-hormone receptor in tendon fibroblasts (Chang et al., Molecules, 2014).
TB-500 / thymosin beta-4 is the more systemically-studied. Thymosin beta-4 is the principal G-actin-sequestering peptide in cells, and that actin-binding activity underlies both cell migration and angiogenesis. In a rodent wound model, topical or intraperitoneal thymosin beta-4 increased re-epithelialization by 42% at day 4 and by as much as 61% at day 7 versus saline controls (Malinda et al., J Invest Dermatol, 1999). A seven-amino-acid actin-binding motif was shown to be essential for its angiogenic activity (Philp et al., FASEB J, 2003). In a mouse cardiac model, thymosin beta-4 activated integrin-linked kinase and promoted cardiac cell migration and survival after infarction (Bock-Marquette et al., Nature, 2004).
The honest framing: this is a deep preclinical file (rodent and in-vitro) with essentially no controlled human evidence. A 2025 systematic review of BPC-157 in orthopaedic sports medicine catalogued 36 studies, of which 35 were preclinical and only one was a small retrospective human case series, and it reported that robust human efficacy and safety data remain absent (Vasireddi et al., HSS Journal, 2025). Anyone selling this as clinically settled science is overstating what exists.
Lab-prep reconstitution math for a blended vial
This is concentration arithmetic for preparing a laboratory reference solution. It tells you how much peptide sits in a given volume of solvent. It is not a dosing schedule and says nothing about route of administration.
The only formula you need:
concentration (mg/mL) = peptide mass in the vial (mg) ÷ volume of bacteriostatic water added (mL)
For a blended vial, run the formula once per peptide, because both are present at once. Using a representative 20 mg Wolverine vial (10 mg BPC-157 + 10 mg TB-500):
| Bacteriostatic water added | Total peptide conc. | BPC-157 conc. | TB-500 conc. | Peptide mass in a 0.10 mL aliquot |
|---|---|---|---|---|
| 1 mL | 20 mg/mL | 10 mg/mL | 10 mg/mL | 1.0 mg + 1.0 mg |
| 2 mL | 10 mg/mL | 5 mg/mL | 5 mg/mL | 0.5 mg + 0.5 mg |
| 3 mL | ~6.67 mg/mL | ~3.33 mg/mL | ~3.33 mg/mL | ~0.33 mg + 0.33 mg |
| 5 mL | 4 mg/mL | 2 mg/mL | 2 mg/mL | 0.2 mg + 0.2 mg |
Reading the table: because the peptides are co-lyophilized in a fixed 1:1 ratio, the ratio never changes with dilution, only the absolute concentration does. Adding more solvent makes a more dilute solution of both; it cannot separate them.
Handling notes that actually change your numbers:
- Solvent. Bacteriostatic water (sterile water with 0.9% benzyl alcohol) is the usual multi-draw diluent because the preservative tolerates repeated needle entry over a storage window; plain sterile water does not. That is a reconstitution detail, not a route-of-administration claim.
- Technique. Add the water slowly down the inside wall of the vial and swirl gently. Do not spray it onto the powder cake and do not shake; these peptides are shear-sensitive, and foaming makes the meniscus hard to read.
- Trust the COA, not the cap. The “10mg/10mg” on the vial is nominal. If a lot-matched COA reports, say, 9.6 mg of measured peptide for one component, the true concentration is 9.6 ÷ your solvent volume. This is exactly why lot-matched testing matters: without it, every figure in the table above is a guess.
Where to buy: vet on checkable signals, not vibes
The research-peptide market is thin on accountability, so rank vendors only on things you can independently verify before you pay. Marketing adjectives (“pharmaceutical-grade,” “99%+,” “trusted”) are not evidence. These six signals are.
| Verification signal | What the gold standard looks like | Why it matters |
|---|---|---|
| Named third-party lab | An independent lab named on the COA (e.g., Janoshik, Freedom Diagnostics) | An unnamed “in-house lab” is not third-party testing |
| Independently verifiable report | A COA you can re-check at the lab’s own site (e.g. by accession number) | If you cannot re-pull it at the source, a screenshot proves little |
| Report visible pre-purchase | You can read the actual COA before checkout | Post-purchase or “email us for the COA” defeats the point |
| Analytical methods | HPLC (purity %) plus mass spec (identity/mass) | HPLC alone does not confirm it is the right molecule |
| Purity figure | A stated purity % tied to that report’s HPLC trace | A number with no trace behind it is decoration |
| Shipping + payment | Truthful origin (“ships from the US”) and working payment rails | Vague origin and vapor checkout are red flags |
Hold every vendor to this list, including the one recommended below and any competitor. Vendors that publish genuine Janoshik or Freedom Diagnostics COAs do exist in this space; when you find one, confirm you can independently re-pull that report at the lab’s own site, because a real lab report you cannot verify at the source tells you nothing. If a seller cannot show you a third-party COA you can independently verify before you pay, treat the purity claim as unverified and move on.
Disclosed recommendation
Disclosure: This guide is published by Pepora (peporalabs.com). We operate the store we recommend and earn a commission when you buy through our coupon code. We rank on lab-verifiable criteria only, and we tell you exactly what to check so you can confirm the claims yourself instead of taking our word for it.
Measured against the six signals above, the Pepora Wolverine (BPC-157 + TB-500) blend is what I point researchers to, for reasons that are all checkable before you spend a dollar:
- Third-party lab, named. Pepora’s core products are tested by Freedom Diagnostics, a US lab running HPLC, UV, and mass spectrometry, not an anonymous in-house bench. Its TB-500, for example, reported 99.70% purity (alongside Tesamorelin at 99.35% and GHK-Cu at 99.98%).
- Results you can verify at the source. Each report is verifiable by accession number at FreedomDiagnosticsTesting.com, so you confirm the lab’s figures yourself rather than trusting a screenshot. Pepora is expanding third-party testing across the rest of the catalog, including the blend components.
- Ships from the US, stated honestly. The peptides themselves are China-sourced, so no “made in USA” claim is made or would be true.
If a vendor cannot show you a third-party report you can independently verify before you pay, do not buy from them. That failure is the whole test.
Coupon (15% off the BLEND cluster): BLEND15 → Buy the Wolverine blend at peporalabs.com
FAQ
What is the Wolverine peptide blend made of? BPC-157 and TB-500 (a synthetic thymosin beta-4 peptide), co-lyophilized in one vial, usually at a 1:1 mass ratio such as 10 mg + 10 mg. It is a research-use-only material, not an approved drug or a proprietary molecule.
What ratio of BPC-157 to TB-500 is in a Wolverine vial? Most vials are 1:1 by mass, commonly 10 mg of each for 20 mg total. Because they are freeze-dried together, the ratio is fixed: diluting the reconstituted vial changes concentration but never the ratio.
How do I reconstitute a blended vial? Add bacteriostatic water and divide each peptide’s mass by the milliliters added to get its concentration. A 10 mg + 10 mg vial reconstituted with 2 mL yields 5 mg/mL of each. Use the lot’s COA figure, not the label, for the exact mass. This is laboratory concentration math, not a dosing instruction.
Is the Wolverine blend FDA-approved or legal to use in humans? No. Neither BPC-157 nor TB-500 is FDA-approved for human use. BPC-157’s status under the FDA’s Section 503A compounding rules is unsettled: it was placed on the interim Category 2 list, and in 2026 the FDA proposed not adding it (or TB-500) to the 503A Bulks List, pending an advisory-committee review. Both are sold and handled research-use-only, and both sit on the WADA Prohibited List, so their presence is prohibited in tested sport.
How do I know a vendor’s purity claim is real? Demand a third-party COA (for example from Freedom Diagnostics) that you can read before purchase, with HPLC purity plus mass-spec identity, and confirm you can independently verify the report at the lab’s own site. A purity percentage with no traceable lab trace behind it is unverified.
Is there human clinical evidence for the blend? Effectively none. The literature is largely rodent and in-vitro preclinical work on each peptide individually; a 2025 systematic review found robust human efficacy and safety data for BPC-157 absent, and there is no controlled human trial of the two combined.
References
- Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. https://doi.org/10.1016/S0736-0266(03)00110-4
- Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. 2006;24(5):982-989. https://pubmed.ncbi.nlm.nih.gov/16583442/
- Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. https://doi.org/10.1152/japplphysiol.00945.2010
- Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077. https://pubmed.ncbi.nlm.nih.gov/25415472/
- Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. https://pubmed.ncbi.nlm.nih.gov/10469335/
- Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK. The actin binding site on thymosin beta4 promotes angiogenesis. FASEB J. 2003;17(14):2103-2105. https://pubmed.ncbi.nlm.nih.gov/14500546/
- Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. https://pubmed.ncbi.nlm.nih.gov/15565145/
- Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS Journal. Published online July 31, 2025. https://doi.org/10.1177/15563316251355551
Disclosure: This page is operated by Pepora (peporalabs.com), a research-peptide vendor. It is affiliate education, not independent journalism: we recommend our own store and earn from purchases made with code BLEND15. We rank strictly on lab-verifiable criteria (named third-party lab, independently verifiable third-party COAs, HPLC and mass spec) so you can verify the claims yourself. Research use only. Not for human or veterinary use. Nothing here is medical advice.